NO20064672L - Anvendelse av organiske forbindelser - Google Patents

Anvendelse av organiske forbindelser

Info

Publication number
NO20064672L
NO20064672L NO20064672A NO20064672A NO20064672L NO 20064672 L NO20064672 L NO 20064672L NO 20064672 A NO20064672 A NO 20064672A NO 20064672 A NO20064672 A NO 20064672A NO 20064672 L NO20064672 L NO 20064672L
Authority
NO
Norway
Prior art keywords
blood pressure
high blood
renal
secretion
syndrome
Prior art date
Application number
NO20064672A
Other languages
English (en)
Norwegian (no)
Inventor
David Louis Feldman
Steven Zelenkofske
Michaela Dinboeck
Margaret Forney Prescott
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20064672L publication Critical patent/NO20064672L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20064672A 2004-03-17 2006-10-16 Anvendelse av organiske forbindelser NO20064672L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55387704P 2004-03-17 2004-03-17
US55735804P 2004-03-29 2004-03-29
PCT/EP2005/002809 WO2005089731A2 (fr) 2004-03-17 2005-03-16 Utilisation de composes organiques

Publications (1)

Publication Number Publication Date
NO20064672L true NO20064672L (no) 2006-12-14

Family

ID=34962409

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064672A NO20064672L (no) 2004-03-17 2006-10-16 Anvendelse av organiske forbindelser

Country Status (15)

Country Link
US (1) US20080161321A1 (fr)
EP (2) EP1729749A2 (fr)
JP (2) JP2007529459A (fr)
KR (1) KR20070006774A (fr)
AU (2) AU2005224014B9 (fr)
BR (1) BRPI0508880A (fr)
CA (1) CA2558020A1 (fr)
IL (2) IL177831A0 (fr)
MA (1) MA28535B1 (fr)
NO (1) NO20064672L (fr)
NZ (2) NZ549535A (fr)
RU (2) RU2426532C2 (fr)
SG (1) SG153831A1 (fr)
TW (1) TW200605867A (fr)
WO (1) WO2005089731A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050043A1 (es) 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
ITMI20050150A1 (it) 2005-02-03 2006-08-04 Umberto Cornelli Prodotti alimentari
EP1904652A2 (fr) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Polymorphismes de nucleotides simples associes a l'oedeme dose-dependant, et leurs procedes d'utilisation
JP2009512715A (ja) * 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
CN101365435A (zh) * 2006-02-06 2009-02-11 诺瓦提斯公司 有机化合物的组合产品
ITMI20060384A1 (it) 2006-03-03 2007-09-04 Umberto Cornelli Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
US20100029775A1 (en) * 2006-12-15 2010-02-04 Prescott Margaret F Renin inhibitors for the prevention and treatment of hypertension in obese patients
TWI452044B (zh) 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
EP2545920A1 (fr) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Thérapie pour complications du diabète
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AR077428A1 (es) * 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
EP2488661B1 (fr) 2009-10-14 2014-12-24 Oberbauer, Rainer Test de risque de lésion rénale aigüe
US10780143B2 (en) 2012-09-19 2020-09-22 University Of Utah Research Foundation Compositions and methods of use for (pro)renin receptor antagonists
US9586995B2 (en) 2012-09-19 2017-03-07 University Of Utah Research Foundation Compositions and methods of use for (pro)renin receptor
US9573976B2 (en) 2012-09-19 2017-02-21 University Of Utah Research Foundation Antagonist for (pro)renin receptor for the treatment of hypertension and diabetes
WO2016019226A1 (fr) * 2014-08-01 2016-02-04 University Of Utah Research Foundation Compositions et procédés d'utilisation d'antagonistes du récepteur de la (pro)rénine
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
US20170014386A1 (en) * 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
JP6929269B2 (ja) 2015-08-26 2021-09-01 レグルス セラピューティクス インコーポレイテッド 多発性嚢胞腎の処置のための方法
WO2017159574A1 (fr) * 2016-03-18 2017-09-21 テルモ株式会社 Dispositif de mesure de fonction cardiaque, procédé de mesure de fonction cardiaque et programme de mesure de fonction cardiaque
US20240207461A1 (en) 2021-04-21 2024-06-27 Nihon Medi-Physics Co., Ltd. Radioactive antitumor agent
WO2023060237A1 (fr) 2021-10-08 2023-04-13 Regulus Therapeutics Inc. Méthodes et compositions pour le traitement de la polykystose rénale

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
US3931305A (en) 1973-08-20 1976-01-06 Standard Oil Company Terephthalic acid recovery by continuous flash crystallization
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4885292A (en) * 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
CA1334092C (fr) 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
DK0403159T3 (da) 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
US5194605A (en) * 1989-12-08 1993-03-16 Merck & Co., Inc. Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
TW201738B (fr) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
KR100222252B1 (ko) * 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
ZA921381B (en) * 1991-03-01 1992-11-25 Fujisawa Pharmaceutical Co New use of amino acid derivatives
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
TW226375B (fr) 1991-10-24 1994-07-11 American Home Prod
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
EP0699069B9 (fr) 1993-04-27 2003-10-22 Smithkline Beecham Corporation Antagonistes des recepteurs de l'endotheline
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
AU675870B2 (en) 1993-08-18 1997-02-20 Msd K.K. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
WO1996006095A1 (fr) 1994-08-19 1996-02-29 Abbott Laboratories Antagonistes d'endotheline
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (fr) 1994-12-20 1997-08-21 Hoffmann La Roche
TR199800409T1 (xx) 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
JP3087968B2 (ja) 1995-12-20 2000-09-18 山之内製薬株式会社 アリールエテンスルホンアミド誘導体及びその医薬組成物
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
EP0906108B1 (fr) 1996-04-04 2005-06-15 Banyu Pharmaceutical Co., Ltd. Les antagonistes de l'endotheline pour traiter l'insuffisance cardiaque
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
FR2801538B1 (fr) * 1999-11-30 2002-01-11 France Design Systeme de toit rigide escamotable pour structure decouvrable, notamment pour vehicule
CA2420055C (fr) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Agent de reduction du fibrinogene
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JP2005509631A (ja) * 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
BR0310084A (pt) * 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
RU2005102002A (ru) * 2002-06-27 2005-09-20 Актелион Фармасьютиклз Лтд. (Ch) Новые производные тетрагидропиридина
CA2490811A1 (fr) * 2002-06-28 2004-01-08 Novartis Ag Utilisation de composes organiques
WO2004100871A2 (fr) * 2003-05-09 2004-11-25 Pharmacia Corporation Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine
US20070238740A1 (en) * 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
AU2004295092A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
KR20060130619A (ko) * 2004-01-22 2006-12-19 노파르티스 아게 유기 화합물의 조합물
AR047880A1 (es) * 2004-02-17 2006-03-01 Novartis Ag COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS

Also Published As

Publication number Publication date
KR20070006774A (ko) 2007-01-11
CA2558020A1 (fr) 2005-09-29
US20080161321A1 (en) 2008-07-03
RU2006136091A (ru) 2008-04-27
BRPI0508880A (pt) 2007-09-04
JP2011178799A (ja) 2011-09-15
JP2007529459A (ja) 2007-10-25
NZ549535A (en) 2010-11-26
EP1977741A3 (fr) 2009-10-14
EP1729749A2 (fr) 2006-12-13
EP1977741A2 (fr) 2008-10-08
MA28535B1 (fr) 2007-04-03
TW200605867A (en) 2006-02-16
RU2426532C2 (ru) 2011-08-20
IL209964A0 (en) 2011-02-28
AU2005224014A1 (en) 2005-09-29
AU2005224014B9 (en) 2009-08-27
WO2005089731A2 (fr) 2005-09-29
RU2010149052A (ru) 2012-06-10
WO2005089731A3 (fr) 2006-05-11
IL177831A0 (en) 2006-12-31
NZ586285A (en) 2011-12-22
AU2005224014B2 (en) 2009-07-16
AU2009222444A1 (en) 2009-10-15
SG153831A1 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
NO20064672L (no) Anvendelse av organiske forbindelser
Sarafidis et al. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications
CA2358400A1 (fr) Procedes de traitement d'etats associes a l'accumulation d'un excedent de matrice extracellulaire
WO2005082863A3 (fr) Derives heterocycliques
ATE398128T1 (de) Neue purinderivate, deren herstelllung und deren verwendung als arzneimittel
KR20260037123A (ko) 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
CA2442761A1 (fr) Medicaments contenant un inhibiteur de la chymase et des inhibiteurs de l'ace comme principes actifs
US20230107479A1 (en) Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
JP2023030022A5 (fr)
Barnett Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy
NO996275L (no) Blokkering av CD154 for å forhindre avstoetning av bukspyttkjerteltransplantater
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
Paccosi et al. The monocyte chemotactic protein synthesis inhibitor bindarit prevents mesangial cell proliferation and extracellular matrix remodeling
Tsimihodimos et al. Antidiabetic drugs and the kidney
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
CN116115763A (zh) 一种含有h1组胺受体拮抗剂的联合用药物
JP6843812B2 (ja) カジメ抽出物およびこれを活性成分として含む血管疾患を予防または処置するための医薬組成物
TNSN06292A1 (en) Use of renin inhibitors in therapy
Lioudaki et al. Renal Effects of SGLT‐2 Inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks
NZ535199A (en) Use of an inhibitor or antagonist against tissue factor
EP0641569A1 (fr) Agent antiprurigineux
CA2517930C (fr) Pyridylsulfonamidopyrimidines pour le traitement de la nephropathie diabetique
JP2023505448A (ja) フェオホルビド化合物を有効成分として含有する、線維症を予防または治療するための医薬組成物
RU2006119329A (ru) Комбинации ат1-антагонистов, амилорида или триаметерина, и диуретика
Karagiannis et al. Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application